Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Current Assets (2020 - 2025)

Historic Current Assets for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to $14.4 million.

  • Biofrontera's Current Assets fell 1487.21% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 1487.21%. This contributed to the annual value of $20.7 million for FY2024, which is 1029.25% down from last year.
  • Latest data reveals that Biofrontera reported Current Assets of $14.4 million as of Q3 2025, which was down 1487.21% from $18.8 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's Current Assets peaked at $48.5 million during Q3 2022, and registered a low of $10.1 million during Q3 2021.
  • Over the past 5 years, Biofrontera's median Current Assets value was $21.9 million (recorded in 2023), while the average stood at $28.2 million.
  • Per our database at Business Quant, Biofrontera's Current Assets skyrocketed by 37837.62% in 2022 and then tumbled by 4651.14% in 2023.
  • Quarter analysis of 5 years shows Biofrontera's Current Assets stood at $46.4 million in 2021, then dropped by 7.07% to $43.1 million in 2022, then tumbled by 46.51% to $23.1 million in 2023, then fell by 10.29% to $20.7 million in 2024, then tumbled by 30.37% to $14.4 million in 2025.
  • Its Current Assets stands at $14.4 million for Q3 2025, versus $18.8 million for Q2 2025 and $15.3 million for Q1 2025.